Prokaryotic/eukaryotic co-culture as a model forin vitrofunctional validation of a dual and sequential drug delivery system with antimicrobial and bone regenerative features
Related Experiment Video
Updated: Aug 5, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
Published on: April 19, 2024
Miguel Rodrigues1, Giorgia Barbolini1, Maria P Ferraz2
1LAQV-REQUIMTE, FEUP, Department of Mechanical Engineering, University of Porto, Rua Dr Roberto Frias, s/n, 4200-465 Porto, Portugal.
Abstract:
Bacteria-mammalian cell co-cultures can provide information on host-cell responses to biomaterials under bacterial challenge that is not available from separate monocultures. This study established a two-stage osteogenic cell-Staphylococcus aureusco-culture for assessment of a previously developed dual and sequential drug delivery system (DDS) designed to release gentamicin followed by alendronate. MG-63 cells were initially exposed toCFU/ml ofS. aureusfor different periods. An inoculum ofCFU/ml and a 2 h exposure were selected because MG-63 metabolic activity did not differ significantly from the monoculture control at this time point (p> 0.05). These conditions were subsequently transferred to primary human bone-marrow mesenchymal stromal cells. The DDS-containing co-culture exhibited an increasing resazurin signal over 16 d and maintained adherent cells with an organised F-actin cytoskeleton. On day 25, protein-normalised alkaline phosphatase activity was 40 mol µg-1protein in the DDS-containing co-culture, compared with 5 mol µg-1protein in the basal-medium control and 63 mol µg-1protein in the osteogenic-medium control. The model supports preliminary assessment of mammalian-cell compatibility and osteogenic-associated activity during sequential drug release under an initial bacterial challenge.
More Related Videos
12:25Microfluidic Co-culture of Epithelial Cells and Bacteria for Investigating Soluble Signal-mediated Interactions
Published on: April 20, 2010
11:003D Flipwell Engineering for Developing Asynchronous Systems for Toxicologic and Immunomodulatory Therapies in Bacterial, Gut, and Immune Cells
Published on: October 17, 2025